9 completed, 1 recruiting. 10 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 9, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Obesity, Abdominal: new trials by email Literature Review of Obesity, Abdominal trials Research Report on Obesity, Abdominal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity Orforglipron, Placebo - Overweight, Prediabetic State | Phase 3 | Recruiting | Eli Lilly and Company | 2001 | 2026-08-26 | 2026-11-05 |
| Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS Liraglutide Pen Injector [Saxenda], Placebo Liraglutide Pen Injector - Pre Diabetes, Polycystic Ovary Syndrome | Phase 3 | Completed | Woman's | 88 | 2018-09-26 | 2021-06-07 |
| Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management LLLT, Lorcaserin - Overweight, Obese | Phase 3 | Completed | Mayo Clinic | 44 | 2014-06-01 | 2016-11-22 |
| Diet and Body Composition Weight-loss diet strategy (+) exercise (PA), weight loss (-) exercise (PA) - Obesity | Phase 3 | Completed | Ben-Gurion University of the Negev | 224 | 2012-10-01 | 2020-10-23 |
| Vitamin D and Omega-3 Inhibit Metabolic Syndrome low glycemic diet, vitamin D omega-3 - Type 2 Diabetes Mellitus, Hypertension | Phase 3 | Completed | University of Guelph | 40 | 2011-04-01 | 2013-06-13 |
| Grain Exercise Trial - Whole Grain Versus no Grain With or Without Physiotherapy-promoted Exercise for Waist Loss Diet A, Diet B, Physiotherapy - Abdominal Obesity, Cardiovascular Diseases | Phase 2 / Phase 3 | Completed | Lund University | 105 | 2010-08-01 | 2017-06-20 |
| Evaluating the Effects Two Diets Combined With Exercise in Persons With Abdominal Obesity (The SHAPE5 Study) Weight Loss Diets Plus Exercise - Overweight, Obese | Phase 3 | Completed | Johns Hopkins University | 77 | 2009-10-01 | 2013-04-04 |
| The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients Carvedilol CR + Lisinopril, Lisinopril + HCTZ - Abdominal Obesity, Hypertension | Phase 3 | Completed | St. Paul Heart Clinic | 25 | 2007-04-01 | 2013-12-06 |
| Rosuvastatin in Visceral Adiposity Rosuvastatin, Placebo for rosuvastatin - Abdominal Obesity | Phase 3 | Completed | Göteborg University | 54 | 2006-05-01 | 2015-08-24 |
| Growth Hormone Treatment in Men With High Risk of Developing Type 2 Diabetes Mellitus recombinant human growth hormone - Abdominal Obesity, Metabolic Syndrome | Phase 3 | Completed | Göteborg University | 40 | 1999-01-01 | 2008-10-29 |
Obesity (5) · Overweight (5) · Hypertension (3) · Weight Loss (3) · Diabetes Mellitus, Type 2 (2) · Glucose Intolerance (2) · Prediabetic State (2) · Cardiovascular Diseases (1) · Hyperlipidemias (1) · Hypertriglyceridemia (1) · Insulin Resistance (1) · Metabolic Syndrome (1) · Motor Activity (1) · Polycystic Ovary Syndrome (1)
Body Weight (10) · Nutrition Disorders (10) · Nutritional and Metabolic Diseases (10) · Overnutrition (10) · Pathological Conditions, Signs and Symptoms (10) · Signs and Symptoms (10) · Glucose Metabolism Disorders (5) · Metabolic Diseases (5) · Obesity (5) · Overweight (5) · Diabetes Mellitus (4) · Endocrine System Diseases (4) · Vascular Diseases (4) · Body Weight Changes (3) · Cardiovascular Diseases (3)
Exercise (3) · Carvedilol (1) · Diet, Reducing (1) · Growth Hormone (1) · Hydrochlorothiazide (1) · Liraglutide (1) · Lisinopril (1) · Low-Level Light Therapy (1) · Physical Therapy Modalities (1) · Rosuvastatin Calcium (1) · Whole Grains (1) · lorcaserin (1) · orforglipron (1)
Göteborg University (2) · Ben-Gurion University of the Negev (1) · Eli Lilly and Company (1) · Johns Hopkins University (1) · Lund University (1) · Mayo Clinic (1) · St. Paul Heart Clinic (1) · University of Guelph (1) · Woman's (1)
United States (5) · Sweden (3) · Argentina (1) · Canada (1) · China (1) · Czechia (1) · Germany (1) · India (1) · Israel (1) · Japan (1) · Mexico (1) · Puerto Rico (1) · South Korea (1) · Spain (1) · Taiwan (1)
Aaron S Kelly, PhD (1) · Anna Nilsson, MD, PhD (1) · Claes Ohlsson, Professor (1) · Ivana T. Croghan, PhD (1) · John-Olov Jansson, Prof (1) · Kelly A Meckling, PhD (1) · Kerry J Stewart, EdD (1) · Kristjan Karason, MD, PhD (1) · Peggy Dean, PharmD (1) · Staffan Lindeberg, MD PhD (1)
PMID 27708788, PMID 28501343, PMID 28814394, PMID 29142011, PMID 29190720, PMID 29576369, PMID 31075323, PMID 33634382, PMID 33663610, PMID 33938135, PMID 34836081, PMID 35348584, PMID 35657082, PMID 35710599, PMID 38639002, PMID 39901232, PMID 40472282, PMID 41039470, PMID 41612310, PMID 42227111
R01HL092280 (1)